View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

EPA/OCSPP RIN: 2070-AK85 Publication ID: Spring 2025 
Title: N-Methylpyrrolidone (NMP); Regulation Under the Toxic Substances Control Act (TSCA) 
Abstract:

EPA is developing a final rule under the Toxic Substances Control Act (TSCA) to address the unreasonable risk of injury to human health presented by n-methylpyrrolidone (NMP). NMP is a widely used solvent in a variety of industrial, commercial, and consumer applications including the manufacture and production of electronics such as semiconductors, polymers, petrochemical products, paints and coatings, and paint and coating removers. EPA determined that NMP presents an unreasonable risk of injury to health due to the significant adverse health effects associated with exposure to NMP, including developmental post-implantation fetal loss from short-term exposure and reduced fertility and fecundity from long-term exposure. Additional adverse effects associated with exposure to NMP include liver toxicity, kidney toxicity, immunotoxicity, neurotoxicity, skin irritation, and sensitization. TSCA requires that EPA address by rule any unreasonable risk of injury to health or the environment identified in a TSCA risk evaluation and apply requirements to the extent necessary so the chemical no longer presents unreasonable risk. On June 14, 2024, EPA proposed requirements to: prohibit the manufacture (including import), processing, and distribution in commerce and use of NMP in several occupational conditions of use; require worker protections through an NMP workplace chemical protection program (WCPP) or prescriptive controls (including concentration limits) for most of the occupational conditions of use; require concentration limits on a consumer product; regulate certain consumer products to prevent commercial use; and establish recordkeeping, labeling, and downstream notification requirements. The Agency’s development of this rule incorporated significant stakeholder outreach and public participation. EPA's 2020 final risk evaluation for NMP, describing its conditions of use is in docket EPA-HQ-OPPT-2019-0236, with the 2022 revised unreasonable risk determination and additional materials in docket EPA-HQ-OPPT-2016-0743.

 
Agency: Environmental Protection Agency(EPA)  Priority: Economically Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Final Rule Stage 
Major: Yes  Unfunded Mandates: Private Sector 
EO 14192 Designation: Regulatory 
CFR Citation: 40 CFR 751   
Legal Authority: 15 U.S.C. 2605 Toxic Substances Control Act   
Legal Deadline:
Action Source Description Date
NPRM  Statutory  TSCA section 6(c)  12/30/2021 
Final  Statutory  TSCA section 6(c)  12/30/2022 
Timetable:
Action Date FR Cite
NPRM  06/14/2024  89 FR 51134   
Final Rule  04/00/2026 
Additional Information: Docket #: EPA-HQ-OPPT-2020-0744.
Regulatory Flexibility Analysis Required: YES  Government Levels Affected: Federal, State, Tribal 
Small Entities Affected: Businesses  Federalism: Yes 
Included in the Regulatory Plan: Yes 
RIN Information URL: https://www.epa.gov/assessing-and-managing-chemicals-under-tsca/risk-management-n-methylpyrrolidone-nmp  
Sectors Affected: 325 Chemical Manufacturing 
RIN Data Printed in the FR: Yes 
Agency Contact:
Clara Hull
Environmental Protection Agency
Office of Chemical Safety and Pollution Prevention
1200 Pennsylvania Avenue NW, Mail Code 7404M,
Washington, DC 20460
Phone:202 564-3954
Email: hull.clara@epa.gov

Joel Wolf
Environmental Protection Agency
Office of Chemical Safety and Pollution Prevention
1200 Pennsylvania Avenue NW, Mail Code 7404M,
Washington, DC 20460
Phone:202 564-0432
Email: wolf.joel@epa.gov